Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
Myasthenia Gravis and the Complement System
This 45-minute CME-accredited program, hosted by James F Howard Jr, MD, Professor of Neurology, Medicine & Allied Health at The University of North Carolina at Chapel Hill, highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease.
After participating in the activity, learners should be better able to:
- Review the pathophysiology of MG.
- Describe the role of the complement system in MG.
- Descr... |